Company Shield Therapeutics plc

Equities

STX

GB00BYV81293

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Shield Therapeutics plc

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - London S.E. Other stock markets 11:35:16 2024-04-25 am EDT			5-day change	1st Jan Change
1.225 ^GBX	-7.55%		-17.23%	-81.72%

Feb. 22	Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024
Feb. 21	FTSE 100 takes hit ahead of FOMC minutes	AN

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.

Number of employees: 27

GBP in Million	2021	Weight	2022	Weight	Delta
Feraccru 100.0 %	2	100.0 %	4	100.0 %	+194.08%

GBP in Million	2021	Weight	2022	Weight	Delta
United States 64.3 %	0	4.0 %	3	64.3 %	+4,611.48%
Netherlands 32.2 %	1	59.8 %	1	32.2 %	+58.37%
Canada 3.4 %	-	-	0	3.4 %	-
South Korea 0.1 %	1	36.2 %	0	0.1 %	-99.09%

Managers	Title	Age	Since
Gregory Madison CEO	Chief Executive Officer	57	21-05-31
Santosh Shanbhag DFI	Director of Finance/CFO	47	Jan. 15
David Childs COO	Chief Operating Officer	-	11-07-31
Jackie Mitchell CTO	Chief Tech/Sci/R&D Officer	-	11-12-31
Karen Chandler Smith IRC	Investor Relations Contact	-	-
Lucy Huntington-Bailey LAW	General Counsel	-	15-07-31
Andy Hurley PRN	Corporate Officer/Principal	-	23-04-09
Paul Spoors AUD	Comptroller/Controller/Auditor	-	18-12-31

Members of the board	Title	Age	Since
Hans-Peter Hasler CHM	Chairman	68	18-07-25
Peter Llewellyn-Davies BRD	Director/Board Member	66	16-01-31
Maria Lacerca-Allen BRD	Director/Board Member	57	21-05-09
Karl Lundström BRD	Director/Board Member	62	21-05-09
Christian Schweiger FOU	Founder	57	07-12-31
Gregory Madison CEO	Chief Executive Officer	57	21-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	782,056,367	342,057,627 ( 43.74 %)	0	43.74 %

Name	Equities	%	Valuation
Maru AG 20.21 %	158,072,273	20.21 %	4 M p
NESTLÉ S.A. 7.162 %	56,008,541	7.162 %	1 M p
FIL Investment Advisors (UK) Ltd. 5.751 %	44,974,355	5.751 %	1 M p
Jupiter Asset Management Ltd. 4.364 %	34,127,697	4.364 %	872 986 p
Hargreaves Lansdown Asset Management Ltd. 4.344 %	33,968,847	4.344 %	868 923 p
IG Markets Ltd. 3.842 %	30,048,000	3.842 %	768 628 p
Premier Fund Managers Ltd. 3.836 %	30,000,000	3.836 %	767 400 p
LGT Capital Partners AG (Investment Management) 3.669 %	28,697,000	3.669 %	734 069 p
KW Investment Management Ltd. 2.378 %	18,600,000	2.378 %	475 788 p
Christian Schweiger 1.490 %	11,651,713	1.490 %	298 051 p

Shield Therapeutics Plc

Northern Design Centre Baltic Business Quarter

NE8 3DF, Gateshead Quays

+44 1915 118 500

http://www.shieldtherapeutics.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.0132 GBP

Average target price

0.02 GBP

Spread / Average Target

+50.94%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SHIELD THERAPEUTICS PLC	-84.14%	12.88M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.31%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.72%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs